NASDAQ: COLL | Healthcare / Drug Manufacturers / USA |
25.63 | +0.0400 | +0.16% | Vol 339.86K | 1Y Perf 17.01% |
Nov 30th, 2023 16:00 DELAYED |
BID | 25.14 | ASK | 26.26 | ||
Open | 25.59 | Previous Close | 25.59 | ||
Pre-Market | - | After-Market | 25.63 | ||
- - | - -% |
Target Price | 27.40 | Analyst Rating | Strong Buy 1.50 | |
Potential % | 6.91 | Finscreener Ranking | + 37.27 | |
Insiders Trans % 3/6/12 mo. | -/-100/-100 | Value Ranking | + 36.80 | |
Insiders Value % 3/6/12 mo. | -/-100/-100 | Growth Ranking | ☆ 27.45 | |
Insiders Shares Cnt. % 3/6/12 mo. | -/-100/-100 | Income Ranking | — - | |
Price Range Ratio 52W % | 51.12 | Earnings Rating | Sell | |
Market Cap | 835.82M | Earnings Date | 7th Nov 2023 | |
Alpha | 0.01 | Standard Deviation | 0.16 | |
Beta | 0.90 |
Today's Price Range 25.4725.99 | 52W Range 20.8330.22 | 5 Year PE Ratio Range -19.4035.40 |
Summary:
Buy
Technical Indicators: | Neutral |
Moving Averages: | Strong Buy |
Performance | |||
---|---|---|---|
1 Week | -1.57% | ||
1 Month | 17.57% | ||
3 Months | 7.96% | ||
6 Months | 14.68% | ||
1 Year | 17.01% | ||
3 Years | 36.47% | ||
5 Years | 33.56% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 11.74 | |||
ROE last 12 Months | -20.90 | |||
ROA (5Y Avg) | 1.54 | |||
ROA last 12 Months | -4.68 | |||
ROC (5Y Avg) | -17.59 | |||
ROC last 12 Months | -1.24 | |||
Return on invested Capital Q | 1.26 | |||
Return on invested Capital Y | -4.47 | |||
Assets Turnover | 0.40 | |||
Receivables Turnover | 2.30 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-26.30 | ||||
4.88 | ||||
2.80 | ||||
10.80 | ||||
-1.90 | ||||
2.65 | ||||
-1.77 | ||||
5.87 | ||||
1.56B | ||||
Forward PE | 4.78 | |||
PEG | -1.32 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.80 | ||||
1.00 | ||||
0.75 | ||||
3.71 | ||||
-0.30 | ||||
Leverage Ratio | 6.20 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
43.80 | ||||
-3.50 | ||||
27.80 | ||||
-83.50 | ||||
-5.33 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
334.31M | ||||
9.96 | ||||
-1.69 | ||||
100.09 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q03 2023 | 1.11 | 1.21 | 9.01 |
Q02 2023 | 1.11 | 1.13 | 1.80 |
Q01 2023 | 1.20 | 1.18 | -1.67 |
Q04 2022 | 0.88 | 0.98 | 11.36 |
Q03 2022 | 1.04 | 0.96 | -7.69 |
Q02 2022 | 1.15 | -0.04 | -103.48 |
Q01 2022 | 0.82 | 0.42 | -48.78 |
Q04 2021 | 0.86 | -0.73 | -184.88 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
12/2023 QR | 1.30 | -3.70 | Negative |
12/2023 FY | 4.77 | 0.85 | Positive |
3/2024 QR | 1.21 | -11.03 | Negative |
12/2024 FY | 5.44 | -1.98 | Negative |
Next Report Date | - |
Estimated EPS Next Report | 1.11 |
Estimates Count | 4 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 339.86K |
Shares Outstanding | 32.61K |
Shares Float | 31.41M |
Trades Count | 5.54K |
Dollar Volume | 8.73M |
Avg. Volume | 316.08K |
Avg. Weekly Volume | 315.41K |
Avg. Monthly Volume | 343.02K |
Avg. Quarterly Volume | 289.81K |
Collegium Pharmaceutical Inc. (NASDAQ: COLL) stock closed at 25.63 per share at the end of the most recent trading day (a 0.16% change compared to the prior day closing price) with a volume of 339.86K shares and market capitalization of 835.79M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 234 people. Collegium Pharmaceutical Inc. CEO is Joseph J. Ciaffoni.
The one-year performance of Collegium Pharmaceutical Inc. stock is 17.01%, while year-to-date (YTD) performance is 10.47%. COLL stock has a five-year performance of 33.56%. Its 52-week range is between 20.83 and 30.22, which gives COLL stock a 52-week price range ratio of 51.12%
Collegium Pharmaceutical Inc. currently has a PE ratio of -26.30, a price-to-book (PB) ratio of 4.88, a price-to-sale (PS) ratio of 2.80, a price to cashflow ratio of 10.80, a PEG ratio of -1.32, a ROA of -4.68%, a ROC of -1.24% and a ROE of -20.90%. The company’s profit margin is -5.33%, its EBITDA margin is 27.80%, and its revenue ttm is $334.31 Million , which makes it $9.96 revenue per share.
Of the last four earnings reports from Collegium Pharmaceutical Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.11 for the next earnings report. Collegium Pharmaceutical Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Collegium Pharmaceutical Inc. is Strong Buy (1.5), with a target price of $27.4, which is +6.91% compared to the current price. The earnings rating for Collegium Pharmaceutical Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Collegium Pharmaceutical Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Collegium Pharmaceutical Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 11.53, ATR14 : 0.72, CCI20 : 63.86, Chaikin Money Flow : -0.09, MACD : 0.88, Money Flow Index : 71.97, ROC : 4.70, RSI : 66.90, STOCH (14,3) : 78.21, STOCH RSI : 0.12, UO : 47.67, Williams %R : -21.79), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Collegium Pharmaceutical Inc. in the last 12-months were: Dreyer Scott (Sold 31 158 shares of value $844 305 ), Joseph Ciaffoni (Option Excercise at a value of $1 397 657), Joseph Ciaffoni (Sold 162 606 shares of value $3 749 892 ), Kuhlmann Shirley (Sold 39 795 shares of value $976 833 ), Kuhlmann Shirley R. (Sold 17 984 shares of value $390 633 ), Michael T. Heffernan (Option Excercise at a value of $4 623 167), Michael T. Heffernan (Sold 298 612 shares of value $6 727 097 ), Scott Dreyer (Sold 17 834 shares of value $488 554 ), Shirley R. Kuhlmann (Sold 21 811 shares of value $586 280 ), Tupper Colleen (Sold 31 640 shares of value $752 083 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. It is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing and dissolving. Its product Xtampza ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone.
CEO: Joseph J. Ciaffoni
Telephone: +1 781 713-3699
Address: 100 Technology Center Drive, Stoughton 02072, MA, US
Number of employees: 234
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Copyright © 2023. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.
General partner of Finscreener is SLOVAKODATA, a.s.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.